8-Day Rally Sends CME Stock Up 7.3%
CME (CME) stock hit day 8 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 7.3% return. The company has gained about $7.0 Bil in value over the last 8 days, with its current market capitalization at about $102 Bil. The stock remains 23.8% above its value at the end of 2024. This compares with year-to-date returns of 14.6% for the S&P 500.
CME Group’s recent streak reflects analyst optimism, underscored by Piper Sandler raising its price target to $313. The imminent launch of its FanDuel Predicts platform, poised to expand retail engagement, coupled with record October trading volumes driven by robust crypto and metals activity, highlights the exchange giant’s strategic growth and market resilience.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There is a near-equal mix of good and bad in CME stock given its overall Moderate operating performance and financial condition. But keeping in mind its High valuation, we think that the stock is Unattractive (see Buy or Sell CME). Nevertheless, when markets turn, single-asset exposure hurts. Smart financial advisors protect client wealth by working with partners who allocate across multiple asset classes – including the High Quality Portfolio.
For quick background, CME provides global futures and options trading markets, clearing, settling, and guaranteeing services for professional traders, institutions, investors, corporations, and governments.
Comparing CME Stock Returns With The S&P 500
The following table summarizes the return for CME stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CME | S&P 500 |
|---|---|---|
| 1D | 1.4% | -1.7% |
| 8D (Current Streak) | 7.3% | -1.7% |
| 1M (21D) | 5.7% | 1.0% |
| 3M (63D) | 4.0% | 4.5% |
| YTD 2025 | 23.8% | 14.6% |
| 2024 | 15.4% | 23.3% |
| 2023 | 31.3% | 24.2% |
| 2022 | -22.9% | -19.4% |
However, big gains can follow sharp reversals – but how has CME behaved after prior drops? See CME Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 62 S&P constituents with 3 days or more of consecutive gains and 40 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 28 |
| 4D | 8 | 12 |
| 5D | 15 | 0 |
| 6D | 6 | 0 |
| 7D or more | 6 | 0 |
| Total >=3 D | 62 | 40 |
Key Financials for CME (CME)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $5.6 Bil | $6.1 Bil |
| Operating Income | $3.4 Bil | $3.9 Bil |
| Net Income | $3.2 Bil | $3.5 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $1.7 Bil | $1.5 Bil |
| Operating Income | $1.1 Bil | $972.6 Mil |
| Net Income | $1.0 Bil | $908.0 Mil |
While CME stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.